Mefenamic acid
As of the edition of 20 October 2026, Mefenamic acid is a small molecule: marketed, first approved in 1964 (ES); acts on PTGS1 and PTGS2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2017
- Kind
- Small molecule
- Brand name
- Ponstel
- First approved
- 1 February 1964 (ES)
- Approvals on record
- 5 in 5 regions
- Holder of the most recent approval
- Pfizer; 3 holders in all
- Registered trials
- 10, 0 stopped early
- Disease areas
- Urinary and reproductive; Hormones; Nutrition and metabolism; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 4 | 4 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| Phase 4 | 3 | 3 | 0 | 0 |
| All trials | 10 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Applicant and Earlier holder | 2017 to now |
| Avion Pharmaceuticals | Acquired holder | 2020 to now |